Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market by Product Type, End User and by Region-Trends and Forecast to 2025

This report studies the global Glucagon Like Peptide-1 (GLP-1) Agonists market status and forecast, categorizes the global Glucagon Like Peptide-1 (GLP-1) Agonists market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America).
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44% in 2015.

The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28% in 2015.

Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK, Sanofi are the leader of the industry, and hold the key technologies and patents, with high-end customers. They have formed global market channel of the industry. However, with the future expanding market, there will be more manufacturers in the future.

The global Glucagon Like Peptide-1 (GLP-1) Agonists market is valued at 5240 million US$ in 2017 and will reach 14200 million US$ by the end of 2025, growing at a CAGR of 13.3% during 2018-2025.

Request Sample Copy of Report @ https://www.qyresearch.com/sample-form/form/341830/global-glucagon-like-peptide-1-glp-1-agonists-sales-market

The major players covered in this report

Novo Nordisk

AstraZeneca

Eli Lilly

GSK

Sanofi

Bristol-Myers Squibb

Amylin

...

Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering

United States

Europe

China

Japan

Southeast Asia

India
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

Exenatied

Liraglutide

Lixisenatide

Albiglutide

Dulaglutide

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

Hospital

Pharmacy

Other

Benefits of Purchasing QY Research Report
• Analyst Support: Get you query resolved from our expert analysts before and after purchasing the report
• Customer’s Satisfaction: Our expert team will assist with all your research needs and customize the report
• Inimitable Expertise: Analysts will provide deep insights about the reports
• Assured Quality: We focus on the quality and accuracy of the report

Buy Full Report Now, Report delivery time within 24 hours @ https://www.qyresearch.com/settlement/pre/a62bb9cf9b0eae4916d80531f68d06c0,0,1,Global%20Glucagon%20Like%20Peptide-1%20GLP-1%20Agonists%20Sales%20Market%20Report%202018

About Us:
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Contact US:
QY Research, INC.
17890 Castleton,
Suite 218,
Los Angeles, CA – 91748
USA: +1 626 295 2442
Email: enquiry@qyresearch.com
Web: http://www.qyresearch.com

This release was published on openPR.